Reference — Lab
Coagulation Studies Reference
PT/INR, aPTT, Anti-Xa, fibrinogen, and d-dimer — normal ranges, anticoagulant monitoring targets, reversal agents, and clinical significance for bedside nursing and NCLEX.
Educational use only. Anticoagulant protocols and therapeutic ranges vary by institution and indication. Always follow your facility's anticoagulation management guidelines. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Coagulation Tests
| Test | Normal | Elevated When | Monitoring Use | Nursing Action |
|---|---|---|---|---|
| PT (Prothrombin Time) | 11–13.5 seconds | Warfarin use (therapeutic), vitamin K deficiency, liver disease, DIC, factor deficiencies (VII, X, V, II) | Used to monitor warfarin — reported as INR for standardization | Therapeutic range for most indications: INR 2–3. Draw before next warfarin dose. Assess for bleeding: black/tarry stool, hematuria, bruising, gum bleeding |
| INR (International Normalized Ratio) | 0.8–1.2 (not on anticoagulation) | Warfarin therapy, vitamin K deficiency, liver disease, DIC | Target INR 2–3 for DVT/PE/atrial fibrillation; 2.5–3.5 for mechanical heart valves | INR > 3.5: hold warfarin, notify provider. INR > 5 or active bleeding: warfarin reversal (vitamin K, FFP, 4-factor PCC). Never hold warfarin without contacting provider first |
| aPTT (Activated Partial Thromboplastin Time) | 25–35 seconds | Heparin (therapeutic), hemophilia A (Factor VIII) or B (Factor IX), DIC (early), antiphospholipid syndrome (lupus anticoagulant), liver disease, vWD (severe) | Used to monitor unfractionated heparin (UFH) — therapeutic aPTT typically 60–100 seconds (or 1.5–2.5 × control per facility) | Check aPTT 4–6 hours after heparin dose change. aPTT > 100 sec: hold heparin, notify provider. Monitor for bleeding. Reversal agent: protamine sulfate (1 mg per 100 units UFH) |
| Anti-Xa Level | Not applicable (therapeutic range varies by drug and indication) | Excessive anticoagulation — risk of bleeding | LMWH therapeutic range (BID dosing): 0.6–1.0 units/mL; daily dosing: 1.0–2.0 units/mL. Draw 4 hours post-dose. Used when aPTT unreliable (lupus anticoagulant, antiphospholipid syndrome) | Required for patients with renal impairment on enoxaparin (risk of accumulation). Monitor for bleeding. Protamine partially reverses LMWH (≈ 60–75% effective) |
| Fibrinogen | 200–400 mg/dL | Acute phase reactant — rises with infection, inflammation, MI, stroke | Followed in DIC — fibrinogen falls as clotting factors are consumed | Fibrinogen < 100 mg/dL = critical — replace with cryoprecipitate; assess for active bleeding in DIC |
| D-Dimer | < 0.5 mg/L (or < 500 ng/mL FEU) | DVT/PE, DIC, MI, stroke, infection, surgery, pregnancy, liver disease, cancer, trauma | High sensitivity but LOW specificity — negative D-dimer helps rule out DVT/PE; positive D-dimer is NOT diagnostic | A positive D-dimer alone does not confirm clot — requires imaging (ultrasound for DVT, CT-PA for PE). D-dimer elevated in many non-thrombotic conditions |
Anticoagulant Monitoring Quick Reference
| Drug | Monitor With | Therapeutic Target | Reversal Agent |
|---|---|---|---|
| Warfarin (Coumadin) | INR | 2–3 (most); 2.5–3.5 (mechanical valves) | Vitamin K (slow onset, hours); FFP or 4-factor PCC (rapid, minutes) |
| Unfractionated Heparin (UFH) | aPTT | 60–100 sec (or 1.5–2.5× control) | Protamine sulfate (1 mg per 100 units UFH) |
| Enoxaparin (Lovenox) — LMWH | Anti-Xa (if monitoring needed) | BID: 0.6–1.0; daily: 1.0–2.0 units/mL | Protamine (partial reversal, ≈ 60–75%) |
| Rivaroxaban (Xarelto) — direct Xa inhibitor | Anti-Xa (if needed) | Not routinely monitored | Andexanet alfa (AndexXa) — FDA approved |
| Apixaban (Eliquis) — direct Xa inhibitor | Anti-Xa (if needed) | Not routinely monitored | Andexanet alfa (AndexXa) — FDA approved |
| Dabigatran (Pradaxa) — direct thrombin inhibitor | ECT or TT (rarely used) | Not routinely monitored | Idarucizumab (Praxbind) — FDA approved |
DIC (Disseminated Intravascular Coagulation) Lab Pattern
DIC is characterized by simultaneous clotting AND bleeding — coagulation factors and platelets are consumed faster than they can be produced.
| Lab | In DIC | Why |
|---|---|---|
| Platelets | Low ↓ | Consumed in widespread microvascular clotting |
| PT/INR | Prolonged ↑ | Clotting factors consumed |
| aPTT | Prolonged ↑ | Clotting factors consumed |
| Fibrinogen | Low ↓ | Consumed in clot formation |
| D-Dimer | Markedly elevated ↑↑ | Widespread fibrinolysis of microclots |
DIC causes: sepsis (most common), massive trauma, obstetric emergencies (abruptio placentae, amniotic fluid embolism), malignancy, transfusion reactions.
NCLEX Focus Points
Warfarin vs heparin monitoring: Warfarin → INR (extrinsic pathway, factor VII). Heparin → aPTT (intrinsic pathway).
Vitamin K and warfarin: Warfarin inhibits vitamin K-dependent factors (II, VII, IX, X, Protein C and S). Foods high in vitamin K (leafy greens) decrease warfarin effect. Reversal: vitamin K (slow) or PCC (fast).
D-dimer rule-out: Negative D-dimer rules out DVT/PE with high sensitivity in low-probability patients. Positive D-dimer requires imaging — it does NOT confirm DVT/PE.
DOACs and lab monitoring: Dabigatran, rivaroxaban, apixaban, edoxaban do NOT require routine lab monitoring — this is a major benefit over warfarin. Reversal agents (idarucizumab, andexanet alfa) are available for emergencies.
HIT recognition: Platelet drop > 50% from baseline occurring 5–14 days after heparin exposure. Paradoxically causes thrombosis despite thrombocytopenia. Stop ALL heparin products immediately including flushes.
Related Resources
Standards & sources
Fact-checked Jun 21, 2026This page is written to align with Standard laboratory reference ranges · Clinical & Laboratory Standards Institute (CLSI). It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →